Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

出版年份 2017 全文链接

标题

作者

关键词

出版物

Volume 26, Issue 15_suppl, Pages 2518-2518

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-02-24

DOI

10.1200/jco.2008.26.15_suppl.2518

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started